Xencor Reports Progress in Oncology and Autoimmune Therapies

Xencor ( (XNCR) ) has issued an update.

Xencor, Inc. has shared promising updates regarding its clinical advancements, presenting initial data from Phase 1 studies of its oncology programs XmAb819 and XmAb808, and revealing new programs targeting autoimmune diseases. With a focus on bispecific antibodies and T-cell engagers, the company is poised to address unmet needs in both cancer and autoimmune therapeutic areas. This progress, outlined in a recent presentation and press release, underscores Xencor’s commitment to leveraging its XmAb technology to develop innovative treatments for patients.

Learn more about XNCR stock on TipRanks’ Stock Analysis page.